Member Info for Supermobileman

Only get worse every time spantrout appears.

Nolupus,

Therefore I will answer it for you as you have no answers to my question.

The truth is Robert Zimmer gets nothing from royalties personally from the patented P140 as far as I am aware.

The patented P140 belongs to Immupharma (with CNRS) the company he worked for.

Robert Zimmer is the inventor of patented P140 and NOT the holder of patented P140.

Nolupus,

Look at your posts, you're always asking questions.

Now answer someone else's question for once.

I'll ask you again. If Robert Zimmer is one of the patented P140 holders, what is his personal percentage of royalties he'll be receiving from/with CNRS/Immupharma?

Answer me.

Nolupus,

You keep referring Robert Zimmer as one of the patented p140 holders.

If that is the case, can you tell us what percentage of royalties he'll be personally receiving from/with CNRS and Immupharma in any future licensing deals, commercial deals, etc.

I'm struggling finding an answer for this.

OTM is right. Yeah he's always right!

Since OTM first came onto this board with his blazing deramping rage, he has covered all possible scenarios with his predictions ( which changes on a daily basis).

This is what he said with some of his predictions and what he said something like this,

"1p to 2p coming"

"deal with share price at 20p maximum"

"4p coming"

"no deal ever"

"deal by June 2026"

"fundraise coming" (he has been saying this since beginning of summer of last year 2025, and recently now been saying it again. A child could work that out if no deal by 2028).

"deal with Avion at 10p"

"50p possible"

"70p possible"

""deal with share price already priced in"

"deal by July 2026"

"there never been a deal"

"deal by 2027"

"deal with share price at 20-30p"

"there never be a deal"

"I have never called Tim a liar"

"£1 possible"

"they are daydreamers if they think this will go to £1"

etc,

etc,

I haven't got all night posting all that he said.

Yep, nobody can outpredict him!

Why don't you tell all the established blue-chip companies like Rolls-Royce, Astrazeneca, HSBC, BP, Vodafone, IAG, Aviva, etc, etc, that they have a business with revenue and profits, so they no longer need to do AGM anymore.

Nolupus,

That's right, you said it.

Tim was only Chairman of Immupharma. But the previous CEO of Immupharma at the time allowed it to happen.

All those Tim (McCarthy) bashers should get their facts right before posting.

Tim has never been CEO of Incanthera as far as I am aware. He doesn't run the company. He was the chairman. One of the chairman role is facing and communicating with shareholders.

The CEO and co-founder was Simon Ward.

Blimey, someone enthusiastic on a disclaimer statement companies have routinely on their literature.

Roger, you are obviously suffering from Tim Derangement Syndrome. You need to take some medicine.

Your right Revd.

Why wouldn't Lanstead be rewarded? They're the ones who are putting up the money. There wouldn't be an AIM market for small and start up companies without institutional investors.

Look at all the companies on AIM when they needed funds, it is the institutional investors who put the money. They will never muster anything near what is needed from private investors. And when institutional investors dry up, cash starved companies goes bust, suspended, delist, etc.

You all should be glad there are institutional investors and for Lanstead.

The article has nothing to do with IMM directly and clinically speaking.

But the patented P140 are owned by both CNRS and Immupharma. Whoever decides to license it, both CNRS and Immupharma will receive royalty payments as per usual in a licensing deal.

What's wrong? You look upset. You thought I was suspended or banned. Only in your wet dreams.

Having a fixation on me now? Stalking me? You must admire me. Do you want my phone number?

Straight in with his usual personal insults from motormouth OTM.

Post reported.

Avion can't refuse to do Phase 3. There are normally timescales which to conduct it. If it was the case Avion refused for no reasons, they would have had their license revoked by Immupharma by now for breach of contract. This clause is normal in the pharmaceutical licensing agreements.

So why hasn't Avion started Phase 3? and why hasn't Immupharma revoked/terminated Avion's license?

I'll let you work that one out yourself.

Nolupus,

Some years back, you admitted yourself and said you met and spoken to Sylviane Muller.

Do you deny that?

Nolupus the question is simple, did you not repeatedly failed attempts to secure an R&D role with Immupharma and several other companies?

Yes or No?

You're so sure of yourself a fundraise was coming, you went and topped up to 3 million shares. You must be hurting. What an idiot.

Kapiglucagon internal sales forecast is $3 Billion PER YEAR over ten years.

A ten-year sales forecast is almost always presented per year rather than as a single ten-year aggregate.

In the video, Tim Franklin's slide forecast in my opinion is vague and 'incorrectly' written.

$3 Billion in total over ten years would equate to only $300m per year which is far too low and far too conservative. Immupharma said Kapiglucagon if approved, would dominate the markets. The world markets is huge. Based on Immupharma market share forecast in the video, $300m per year or $3Billion over ten years does not add up but $3 Billion per year would be about correct.

Tim McCarthy said "$3 Billion per year" in the video.

Nolupus,

Could you tell us how long Immpharma last Phase 3 trial went on for from 1st dose to results? Was it three years? You certainly have short memories.

It all depends on the number of pateints required by the FDA and the budget of the partner willing to spend. A big pharma with deep pockets can recruit patients a lot quicker by hiring more staff involved in the recruitment process. Immpharma done theirs on a low budget.